Telix to acquire ITM in $1.65B radiopharma merger with up-to-$700M earn-out
Telix Pharmaceuticals will acquire ITM Isotope Technologies in a deal worth at least $1.65 billion, with the potential to pay up to $700 million more if ITM’s lead radiopharmaceutical meets regulatory and sales milestones, creating a larger radiopharma player to compete with Novartis in the growing field.